BackBrii Biosciences Limited Overview

Brii Biosciences Limited Total Current Liabilities

Latest total current liabilities for BRIBF: $34M.

Get informed when a big investor buys or sells

+ Follow
Total Current Liabilities
$34.16M
↓ 29.73% YoYΔ $-14.45M vs prior year quarter

Peer trimmed avg / median

Loading

Brii Biosciences Limited Total Current Liabilities History

Loading

Brii Biosciences Limited vs. peers: Total Current Liabilities Comparison

Loading

Brii Biosciences Limited Total Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Brii Biosciences Limited (BRIBF) FAQ

Brii Biosciences Limited posts a total current liabilities of $34M as of June 2026. That compares with $49M in the prior-year period — down 29.7% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Brii Biosciences Limited's total current liabilities was $49M. The latest reading is $34M — a 29.7% year-over-year decrease (period ending June 2026). Use the history and growth charts on this page for a longer lookback.

Total Current Liabilities is one piece of Brii Biosciences Limited's financial statement story. At $34M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for BRIBF's total current liabilities usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Brii Biosciences Limited's other metric pages and overview cover the third.

Judging Brii Biosciences Limited against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in total current liabilities easier to interpret. Start with $34M here, then scan peer and history charts to see if the gap is persistent.